-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64

Benzinga·08/14/2026 17:25:11
Listen to the news
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and lowers the price target from $66 to $64.